Virus-host cell interactions are most commonly analyzed in cells maintained in vitro as two-dimensional tissue cultures. However, these in vitro conditions vary quite drastically from the tissues that are commonly infected in vivo. Over the years, a number of systems have been developed that allow the establishment of three-dimensional (3D) tissue structures that have properties similar to their in vivo 3D counterparts. These 3D systems have numerous applications including drug testing, maintenance of large tissue explants, monitoring migration of human lymphocytes in tissues, analysis of human organ tissue development and investigation of virus-host interactions including viral latency. Here, we describe the establishment of tissue-like assemblies for human lung and neuronal tissue that we infected with a variety of viruses including the respiratory pathogens human parainfluenza virus type 3 (PIV3), respiratory syncytial virus (RSV) and SARS corona virus (SARS-CoV) as well as the human neurotropic herpesvirus, varicella-zoster virus (VZV).
Introduction
Three-dimensional (3D) tissue culture systems are used in cell biology and physiology, immunology, cancer research, microbiology (bacteriology and virology) and tissue engineering to facilitate investigations in a more physiological setting than is obtained with 2D-tissue culture systems. Many bioreactor systems and other experimental devices have been used to establish 3D tissues that emulate properties similar to human and mammalian tissues in vivo [1] [2] [3] . Here we describe our approach to establish an optimized 3D tissue culture system using a rotating wall vessel (RWV) reactor to study viral infections and virus/host interactions.
Early attempts at 3D tissue culture systems
Tissue culture explant models were established in the 1920s, which allowed maintenance and expansion of organ tissues in culture or on filters [4, 5] . For certain tissues (e.g. skin), it was critical to keep the cultures at the air-liquid interface, thereby providing conditions similar to the in vivo environment [6] . To maintain native tissue architecture, 1-5 mm 2 tissue explants were grown on collagen-coated cellulose sponges surrounded by plasma clots in roller tubes [2, 7] . A number of these systems are well established and widely used in contemporary research. However, the disadvantages of explant systems are that ex vivo tissues from humans are limited and often difficult to obtain. Explant cultures are also short lived and prone to necrosis due to insufficient nutrient and oxygen transfer within the tissue. Furthermore, it remains almost impossible to genetically modify primary tissues, while cultured cells can be readily modified using various targeted genome-editing techniques such as transcription activator-like effector nucleases (TALENS) and clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) [8] [9] [10] . To circumvent these limitations, culture systems have been established that allow de novo assembly of analog 3D tissues for a variety of applications.
The establishment of high-density 3D tissues in vitro using mammalian cells is challenging due to shear forces, turbulence, inadequate oxygenation and restricted nutrient transfer that can disrupt or damage the cultures. Peripheral cells commonly grow readily while cells in the center of the tissue undergo necrosis due to nutrient and oxygen deprivation. To provide a constant source of nutrients, chambers were developed that allowed metabolic exchange between a pool of medium and the culture chamber by diffusion across a membrane. This histo-physiological gradient mimics to some degree, the diffusion of essential nutrients in tissues [7, 11] . To enhance the establishment of 3D tissues in vitro, Nandi and colleagues embedded the cultures in collagenous gels providing a scaffold for tissue growth [12] . The collagen gels allow establishment of mammary-like tissue with ductile structures from mammary cells. These cultures show sustained growth for several weeks and closely resemble the corresponding tissue in vivo [12] . Taken together, the early advances allowed the maintenance of tissue explants and de novo assembly of 3D tissues, while retaining their normal shape and special associations [2] .
Establishment of 3D tissues in bioreactors
To improve the 3D tissue culture systems, bioreactors were introduced. Bioreactors are commonly used to produce pharmaceutical proteins such as interferon, growth hormones, and insulin molecules and to allow the maintenance of stable growth conditions over a long time period. In addition, bioreactors can provide defined culture conditions at exact time points, which is often required for the assembly and differentiation of 3D structures. Basic steps involved in construction of 3D tissue structures include tissue assembly, growth, formation of extracellular matrix (ECM) and basement membranes. Cell differentiation is associated with cellular specialization and vascular (or pseudo-vasculature) formation and is required for the establishment of an ex vivo tissue comparable to their in vivo counterparts ( Fig. 1 ). To achieve this, each 3D tissue structure must be optimized for the following parameters (i) co-location of particles (tissues) of different sedimentation rates, (ii) three-dimensional spacial freedom that maximizes cell-to-cell and cell-to-microcarrier adherence required for assembly of the complex tissues, (iii) extremely low fluid shear stress and turbulence and (iv) oxygenation by active or passive diffusion with the exclusion of all air bubbles and permitting only dissolved gasses to enter/exit the bioreactor chamber thereby yielding a vessel devoid gas/fluid interface (zero headspace) [13, 14] . Standard vertically oriented bioreactors allow minimal assembly of complex functional mammalian tissues; however, the normal fluid mechanical effects in these systems often leads to excessive shear forces, turbulence and in many cases, inadequate oxygenation and nutrient transfer that cause cell death and pose critical barriers to the establishment of the functional 3D culture systems ( Fig. 1 ).
To overcome these problems, NASA engineers and scientists developed the integrated rotating-wall vessel (RWV; US patent 5,026,650; Fig. 2A and B) that allows establishment of 3D tissues on microcarriers or other matrices under near neutral buoyancy, controlled oxygenation, low shear stress and minimal turbulence [13, 15, 16] . The microcarriers serve as structural support for assembly and growth of 3D tissues [17] . Cells efficiently form bead-to-bead or matrix-to-matrix bridges in the RWV bioreactor at low agitation rates [18] , typically resulting in aggregates of approximately 12-15 microcarrier beads. The RWV system eliminates excessive agitation from stirring (vertical bioreactors) and minimizes other shear forces that damage the microcarrier 3D tissues [19, 20] . RVW systems are available in various commercially available volumes and can be scaled up to 1 liter.
One advantage of the RVW system is the high reproducibility and efficiency of establishing 3D tissue-like assemblies (TLAs) with characteristics of human tissues. Numerous publications confirm the similarity of structural organization and biomarker expression on the surface of the TLAs with their in vivo counterparts [21] [22] [23] [24] [25] . For example, we selected both DNA (VZV) and RNA (RSV, PIV3 and SARS-CoV) viruses to infect neuronal or respiratory TLAs, respectively, that were shown by transcript and protein analysis to reflect their physiological counterparts [26] [27] [28] [29] . The unique feature of the RWV system maintains cell viability of the virus-infected TLA tissues for longer time periods than their 2D-tissue culture counterparts. Importantly, high-titer, cell free virus (1 Â 10 5 -10 7 /ml; Hepatitis C, 1 Â 10 5 -10 7 ; RSV; and 1 Â 10 7 /ml, PIV3 5 Â 10 6 ) [25, 28, 30, 31] can be obtained from the supernatants of infected TLAs. Cytopathic effects (CPE) were detected in TLAs infected with SARS and RSV; however, this CPE did not impair the ability of the RWV cultures to replicate. In the case of VZV we succeeded in our objective to construct and infect neuronal TLAs with the virus that remained viable for months during which time the virus/host interaction was monitored [27] . Here we describe the establishment of neuronal and lung (TLAs) in the RWV system that can be infected with various viruses.
Materials and equipment
2.1. Rotating-wall vessel (RWV) bioreactor assembly RWV bioreactors are available as batch fed or continuous flow, and allow tissue growth under 3D conditions in an optimized fluid suspension environment. The system is based on a rotating cylinder completely filled with fluid. Shortly after the cylinder begins to rotate, the fluid in the cylinder becomes coupled to the wall and rotates at the same speed as the vessel and TLAs rotate at the same speed (angular velocity) as their supporting fluid. Since TLAs have a slightly higher density than the fluid, they become suspended without stirring and with extremely low shear (0.15 dynes/cm 2 ). Oxygenation is achieved by passive diffusion to avoid gas bubbles and associated shear forces [14] . 3D cultures in the RWV system ( Fig. 2 ) require the following equipment, materials, media and supplies.
Equipment

Required
Inverted microscope, hemocytometer Reichert, tissue culture incubator with sufficient air flow to dissipate heat (e.g. ThermoForma Model 3950), 1 laminar flow hood, fume hood; autoclave; bench top 4°refrigerated centrifuge, iStat handheld blood gas analyzer, 2 RWV bioreactor and power supply, model number RCCS1, Synthecon, 3 Milli-Q water system, 4 50-micron polyester mesh, No. 7-51/36 5 
Culture media and supplements
We developed a unique media for all cultures and tissue engineering described in this article termed GTSF-2 [32] (patented) that is commercially available at GE Healthcare LifeScience 12 . It consists of 40% MEM (Alpha Mod), 60% L-15 Leibovitz Medium, with HEPES (SH3A099 12 ) supplemented with NaHCO 3 1.35 g/l Sigma/S-5761 11 , HEPES 3.0 g/l Research Organics/6003H-2, 13 Folic acid 6.667 lg/l Sigma/F-8758 13 and 0.5% Nicotinic acid 0.667 ml/l Sigma/N-4126 11 , Bactopeptone 0.6 g/l Difco/0118-01 1 , i-lnositol 0.024 g/l Sigma/l-5125 11 , Fructose 0.1 3 g/l Sigma/F-3510 11 , Galactose 0.25 g/l Sigma/G-5388 13 , D-Glucose 0.25 g/l Sigma 11 , 300 mM L-Glutamine 10 ml/l Sigma/G-5763 11 , 10 ml/l penicillin-str eptomycin, No. 15140-122 Gibco/life technologies, 14 ThermoFisher Scientific, Waltham, MA 1 ), Fungizone 2 ml/l 15290-018 Gibco/Life Technologies, ThermoFisher Scientific, Waltham, MA, 1 Insulin-trans ferrin-sodium-selenite 5 ml/l Sigma/l-1884 11 and 7-10% fetal bovine serum Hyclone 12 . Serum concentration is dependent on cell line requirements. 10x Calcium/Magnesium-free phosphate buffered saline (PBS) containing 2 g/l KCl, 2 g/l KH 2 PO 4 , 11 g/l Na 2 HPO 4 and 80 g/l NaCl; 0.2% trypsin/0.1% EDTA solution; Trypan blue stain, No. 630-5250. 14 
Optional reagents for electron microscopy
Cells and viruses
Primary cells and stable cell lines were used to establish various 3D tissues as shown in Table 1 [15, 17, 21, 22, 27] . Human lung TLAs were established using primary human bronchio-tracheal cells (HBTCs) 18 (Cambrex BioWittaker, San Diego, CA) and BEAS-2B cells, an SV-40 transformed human bronchial epithelial cell line from ATCC 19 (Rockville, MD). Cells were propagated in GTSF-2 media as described previously [15] . For the establishment of human neuronal TLAs, we used normal human neural progenitor (NHNP) cells (Lonza 20 ; Walkersville, MD, USA). NHNPs from multiple donors were initially propagated in GTSF-2 on human fibronectin-coated flasks 21 (BD Biosciences, San Jose, CA) and pooled from at least five donors as described previously [32] (US patent 5,846,807 and 5,858,783). Stock cultures were prepared, tested for viral contaminants as described by the manufacturer and stored in liquid nitrogen. All cells and viruses used to infect RWV 3D tissues were either generated by us (VZV) [27, 33, 34] or obtained through ATCC Rockville MD 19 (SARS-CoV, RSV and PIV3).
Preparation of material and RWV bioreactor
Microcarrier preparation
Microcarriers are prepared two days before initiation of an RWV experiment. Prepare four 50-ml autoclavable corning tubes with a 20 mg/ml stock suspension of Cytodex-3 11 or 3 mg/ml Cultispher 11 microcarriers for each bioreactor. Steps 3-7 are performed in a laminar flow hood to avoid contamination.
(1) Add 1 g of dry microcarriers into each of the four tubes.
(2) Sterilize 500 ml of calcium-and magnesium-free 1Â PBS by filtration (0.22 lm filter) or purchase sterile PBS.
(3) Add 50 ml of PBS to each microcarrier tubes and incubate at room temperature (RT) overnight. (4) Autoclave microcarriers in PBS in corning tube with caps loosened for 15 min at 110°C (liquid cycle) with slow cool down. (5) Aspirate PBS and resuspend microcarriers in 50 ml of growth media.
RWV preparation
The RWV bioreactor should be disassembled and properly cleaned prior to use as described below.
(1) Remove center bolt at top of the RWV bioreactor using an Allen wrench. filled syringe with sterile growth media to compensate for evaporation through the oxygenator and one empty syringe for the removal of air bubbles. (5) Fill vessel to 50% of total volume with growth medium, allowing space for the microcarriers and cells for the establishment of the TLA culture. bubbles beneath syringe ports and use empty syringe to pull bubbles out. (6) Once bubbles are removed, apply slight head pressure to RWV using syringe with media to restore the culture volume. (7) Once slight head pressure achieved, close both syringe ports and thoroughly examine if RWV assembly has any leaks. Transfer vessel from laminar flow hood to humidified CO 2 incubator and screw onto base. Set initial rotation speed to 18-20 rpm. Check again after 1 h for appropriate rotation speed, potential leaks and lack of bubbles. (8) Monitor vessel metabolism every 24 h using the iStat handheld blood gas analyzer 2 according to the manufacturer's instructions. The following 13 basic physiological parameters were analyzed: glucose concentration, Cl/Na/K ion concentrations, pH, partial pressure of CO 2 (PCO 2 ), bicarbonate concentration (HCO 3 ), total CO 2 (TCO 2 ) anion gap, base excess, hematocrit (Hct), hemoglobin (Hgb), blood urea nitrogen (BUN). These metabolic levels should be stably maintained at physiologic levels.
General protocol for establishment and maintenance of TLAs
Human lung TLAs
HBTCs were injected at a density of 2.5 Â 10 5 /ml in 1.0 ml along with 3 mg/ml Cultispher G microcarriers, into a 55.0 ml NASA RWV bioreactor and allowed to attach and assemble for 48 h at 18-20 rpm. The Cultispher G beads functioned as support matrix for the attachment of the HBTCs, which provide a mesenchymal and endothelial cell (basal cell layer). At 48-72 h post HBTCs Unsworth and Lelkes [24] inoculation, 3.5 Â 10 5 BEAS-2B cells were added to the RWVs. The BEAS-2B cells adhered to the existing bead-cell matrix and the co-culture continuously develops until the TLAs reach a size of 3-5 mm. Cultures were then ready for infection with either SARS-CoV [29] , human parainfluenza virus type 3 (PIV3), respiratory syncytial virus (RSV) [21, 22, 26, 28] .
Normal human neural progenitor TLAs
3D NHNP TLAs were generated by seeding 3.5 Â 10 5 NHNP cells/ml and 3 mg/ml Cultispher 11 beads into a 55 ml RWV and grown at 37°C under a 5% CO 2 . Cells were allowed to attach to the beads for 48 h in the bioreactor before re-feeding with GTSF-2 containing 10% FBS. To maintain the TLA cultures within normal human physiological blood chemistry parameters (80-120 mg/dL glucose and pH 7.2), 20-90% of the media was replaced as required with fresh GTSF-2 media every 24-48 h, thus facilitating efficient TLA tissue growth. All metabolic determinations were made using an iStat analyzer as described above. Gently press on compliant syringe originally placed on vessel at time of inoculation and pull on empty sample syringe to remove sample (two syringes). This step must be done while vessel is rotating to prevent sedimentation of the TLAs during sampling; therefore, care must be taken to prevent syringes from detaching from the vessel. (3) When desired volume of sample has been removed and replaced with equal volume of fresh medium from compliance syringe, turn off power. Close valve on sampling syringe port and remove sampling syringe. Repeat this step if multiple samples are required. (4) Replace Lure lock cap and turn on rotator power. Note: we routinely take samples every 24-48 h and analyze them by light microscopy, RT-PCR, proteomics (Luminex), SEM or ESEM. In addition, cells can be dissociated from microcarriers to determine viability and concentration. (5) TLA Culture Monitoring procedure 3D TLA cultures are monitored daily using the iStat as described above.
Media change in RWV bioreactor
Infection of RWV cultures
Preparation of cell-free viruses
All virus cultures in this article were prepared by a similar protocol. Cell-free virus SARS-CoV, RSV, PIV3 and VZV [27, 35, 36] was used for TLA infections to avoid cellular contamination of the TLA cultures. In the case of each virus, infected cells were harvested at 96 h post-infection (p.i.) of infected tissue cultures and resuspended in reticulocyte standard buffer (10 mM NaCl, 1.5 mM MgCl 2 , 10 mM Tris-HCl, pH 7.4). The cells were disrupted by 20-25 strokes of a Dounce (type A) homogenization, debris was centrifuged at 9000Âg for 15 min and supernatant containing virus filtered through a 1.0 mm Millex [25] filter unit.
Viral inoculation
TLA constructs in the RWV were infected with cell-free virus. Multiplicities of infection (MOI) varied for each virus from 0.01 (RSV, PIV3 and SARS) to 0.1 (VZV) determined by plaque assay and cell counts [26] [27] [28] [29] 34] .
(1) For the inoculation, follow the protocol outlined in Section 4.3. At step Section 4.3(4) the inoculum is injected into the bioreactor before replacing the removed volume with fresh media. (2) Inoculate the RWV with the desired virus at the appropriate MOI in 20 ml GTSF-2 in the vessel and allow to absorb at 35°C (lung TLAs) and 37°C (NHNP TLAs) for 30 min in a CO 2 incubator. (3) Then fill the RWVs with fresh GTSF-2/8% FBS and transfer to a humidified incubator with a 5% CO 2 at 37°C following steps Section 4.3(4-9). (4) Every 24 h.p.i., replace 80% of the culture media with fresh GTSF-2 or media of choice containing 8-10% FBS. (5) Samples can be collected every desired intervals for viral titration, biochemical analysis or TLAs analyses.
Analysis of virus infected TLAs
Sample preparation for analysis of VZV, SARS-CoV, RSV or PIV3 infected TLAs
(1) Samples are taken from the cultures as described in Section 4.4 at the desired intervals. (2) TLAs and culture supernatant are gently deposited into 15 ml conical tubes (as needed) and allowed to stand until the aggregates are sedimented.
(3) Remove the culture supernatant and centrifuge at 9000 g to remove any cell debris and transfer to 2 ml aliquots in cryovials and freeze at À80°C for later analyses (proteomics/Luminex, metabolomics and viral assays). (4) Wash TLAs with calcium and magnesium free PBS (2Â) and place in either the appropriate SEM or immunohistochemistry fixative. Some unfixed samples may be placed in 1 ml cryovials for flash freezing at À196°C or at À80°C for DNA or RNA analyses (RT-PCR, Transcriptome).
6.2. Electron microscopy protocols (Optional) 6.2.1. Scanning electron microscopy (SEM, Fig. 3) (1) Make a solution of 0.1 M cacodylic buffer prior to analyses and store at 4°C; prepare 1.0% saturated Thiocarbohydrazide (TCH) by stirring for 24 h before sample preparation. Filter solution with a Corning disposable filter unit just before using to remove any crystals. Solution is light sensitive keep in dark bottle and protected by wrapping in aluminum foil (shelf life 5 days). Repeat for all samples. Place capsules in 50-ml tube. Add 10 ml of OsO4 solution to each tube and allow to fix for 45-60 min. Swirling tube intermittently to move the solution. Cover with foil to protect from light. Rinse sample very well with deionized water. (7) Next add 10-ml filtered 1.0% TCH solution to sample tubes and as before swirl tube and allow to fix for 10 min. Again, protect from light. Then rinse 5Â times for 5 min each with deionized H 2 O. (8) Fix samples again for 10 min by adding 10 ml of OsO4 solution while protecting from light and rinse 4Â for 5 min each with deionized H 2 O (9) Perform sequential dehydration using increasing concentrations of ethanol as follows: 20% for 5 min, 50% for 5 min, 75% for 5 min, 95% for 5 min, 100% 2 Â 5 min. Samples are ready for dehydration with hexamethyldisilazane (HMDS) or critical-point drying. (12) Analyze the plaques by fluorescent microscopy.
Future directions
The TLA models for human lung and neuronal tissues using RWV bioreactors provide a very versatile tool. The tissues can be maintained for several months and allow the infection with a number of viruses. Both DNA (VZV) and RNA (SARS-CoV, PIV3 and RSV) viruses have been used to infect these systems to analyze infection in a more physiological setting [26] [27] [28] [29] . We recently demonstrated that VZV can establish a persistent infection in these NHNP TLAs, which can be maintained for at least 3 months [27] . This system The integrated nature and alignment of the neural TLA is similar to the native neural tissues ex vivo (D). Images were taken using a FEI Quanta 250 environmental scanning electron microscope. 8 will provide the basis for future studies to decipher the establishment of VZV latency and reactivation. The use of genetically modified NHNP cells would provide a suitable system to address the cellular factors that influence VZV latency. Similarly, neuronal TLAs could be used as a system to study other neurotropic viruses such as herpes simplex (HSV), Dengue and West Nile viruses. Similarly, lung TLAs can be infected with SARS for up to 10 days proving a system that more closely resembles the infection in vivo. Intriguingly, TLAs can be seeded with various immune cells [23, 37] , allowing analyses of virus infection in the presence of defined components of the immune system. Furthermore, production of live attenuated VZV vaccines is difficult due to the highly cell-associated nature of the virus. However, the virus is cell-free in the skin lesions of chicken pox. Engineering skin TLA may provide the cell system required to generation of high-titer, cell free attenuated virus for vaccine production.
